Follow the people · Insider
Ronit Satchi-Fainaro
Ronit Satchi-Fainaro files insider transactions with the SEC as a director of Teva Pharmaceutical Industries (TEVA). We hold 1 disclosed purchase or sale filed since 7 June 2018, 1 of them in the last 90 days.
- Files forTEVA
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure25 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 5 June 2018 — 21 August 2026Director · Teva Pharmaceutical Industries (TEVA)27 Form 4 lines · source: SEC Form 4
Everything they disclosed
27 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 415 shares of Teva Pharmaceutical IndustriesSEC Form 425 August 2026Ordinary Shares · traded 21 August 2026 · filed 25 August 2026
- exercised options over 14,492 shares of Teva Pharmaceutical IndustriesSEC Form 48 June 2026Ordinary Shares · traded 5 June 2026 · filed 8 June 2026
- exercised options over 14,492 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 48 June 2026Restricted Share Units · traded 5 June 2026 · filed 8 June 2026
- was granted 7,242 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 41 June 2026Restricted Share Units · traded 28 May 2026 · filed 1 June 2026
- exercised options over 9,632 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 49 June 2025Restricted Share Units · traded 6 June 2025 · filed 9 June 2025
- was granted 14,492 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 49 June 2025Restricted Share Units · traded 5 June 2025 · filed 9 June 2025
- exercised options over 9,632 shares of Teva Pharmaceutical IndustriesSEC Form 49 June 2025Ordinary Shares · traded 6 June 2025 · filed 9 June 2025
- exercised options over 21,108 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 417 June 2024Restricted Share Units · traded 15 June 2024 · filed 17 June 2024
- exercised options over 21,108 shares of Teva Pharmaceutical IndustriesSEC Form 417 June 2024Ordinary Shares · traded 15 June 2024 · filed 17 June 2024
- was granted 9,632 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 410 June 2024Restricted Share Units · traded 6 June 2024 · filed 10 June 2024
- exercised options over 15,810 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 47 August 2023Restricted Share Units · traded 4 August 2023 · filed 7 August 2023
- exercised options over 15,810 shares of Teva Pharmaceutical IndustriesSEC Form 47 August 2023Ordinary Shares · traded 4 August 2023 · filed 7 August 2023
- was granted 21,108 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 420 June 2023Restricted Share Units · traded 15 June 2023 · filed 20 June 2023
- was granted 15,810 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 48 August 2022Restricted Share Units · traded 4 August 2022 · filed 8 August 2022
- exercised options over 14,479 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 416 June 2022Restricted Share Units · traded 14 June 2022 · filed 16 June 2022
- exercised options over 14,479 shares of Teva Pharmaceutical IndustriesSEC Form 416 June 2022Ordinary Shares · traded 14 June 2022 · filed 16 June 2022
- acquired or disposed of by will or inheritance 550 shares of Teva Pharmaceutical IndustriesSEC Form 416 June 2021Ordinary Shares · traded 9 June 2021 · filed 16 June 2021
- was granted 14,479 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 416 June 2021Restricted Share Units · traded 14 June 2021 · filed 16 June 2021
- exercised options over 12,668 shares of Teva Pharmaceutical IndustriesSEC Form 410 June 2021Ordinary Shares · traded 9 June 2021 · filed 10 June 2021
- exercised options over 12,668 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 410 June 2021Restricted Share Units · traded 9 June 2021 · filed 10 June 2021
- exercised options over 6,041 shares of Teva Pharmaceutical IndustriesSEC Form 48 June 2021Ordinary Shares · traded 5 June 2021 · filed 8 June 2021
- exercised options over 6,041 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 48 June 2021Restricted Share Units · traded 5 June 2021 · filed 8 June 2021
- exercised options over 17,621 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 415 June 2020Restricted Share Units · traded 11 June 2020 · filed 15 June 2020
- exercised options over 17,621 shares of Teva Pharmaceutical IndustriesSEC Form 415 June 2020Ordinary Shares · traded 11 June 2020 · filed 15 June 2020
- was granted 12,668 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 411 June 2020Restricted Share Units · traded 9 June 2020 · filed 11 June 2020
- was granted 17,621 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 413 June 2019Restricted Share Units · traded 11 June 2019 · filed 13 June 2019
- was granted 6,041 shares of Teva Pharmaceutical Industries (a derivative holding)SEC Form 47 June 2018Restricted Share Units · traded 5 June 2018 · filed 7 June 2018
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.